The Medicines Co. Prepares To Move Into New Commercial Territory
This article was originally published in The Pink Sheet Daily
Executive Summary
With the release of positive Phase III data on the antibiotic oritavancin, the hospital specialist soon could be making a commercial foray into an area outside its current expertise in cardiovascular disease.
You may also be interested in...
Oritavancin Phase III Results Support FDA’s New Endpoint, Sponsor Says
FDA’s new early endpoint for efficacy in ABSSSI had been criticized at the time it was released. But reporting positive results for a second Phase III study of oritavancin, The Medicines Co CEO says the agency’s ABSSSI endpoints are “appropriate” for industry.
Antibiotic Market Snapshot: In Exchange For Higher Prices, More Value
Drug developers face enormous regulatory and commercial hurdles in the antibiotics market, but industry is looking to challenge the current business model with new premium-priced drugs that deliver compelling pharmaco-economic benefits over generics.
With GAIN In Place, Antibiotic Improvements Depend On FDA Implementation
FDA and industry are turning their attention to implementation of the Generating Antibiotic Incentives Now provisions of PDUFA V, which include an additional five years of marketing exclusivity for certain products and new guidance aimed at streamlining the drug development process.